Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

Behind the Scenes of the Oncology & Precision Medicine Conferences 2022

During the conference, we caught up with some of the speakers to learn more about their work, what they were presenting, and their thoughts about the future of Oncology and Precision Medicine.

15 Nov 2022

High-intensity aerobic exercise can cut metastatic cancer risk by 72%

A new study at Tel Aviv University found that aerobic exercise can reduce the risk of metastatic cancer by 72%.

14 Nov 2022

Popular dietary supplement linked to cancer risk, brain metastasis

Researchers develop a new method to map the spatial evolution of cancers

Researchers developed a genetic clone mapping workflow centered around base-specific in situ sequencing (BaSISS) technology to derive quantitative maps of multiple genetic clones of cancer cells.

11 Nov 2022

Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancer

For patients with solitary metastases from prostate cancer, an approach called metastasis-directed therapy (MDT) – focused treatment using surgery or radiation therapy, without androgen deprivation therapy (ADT) – can slow the time to cancer progression, reports a study in The Journal of Urology, an Official Journal of the American Urological Association

10 Nov 2022

Researchers illuminate the role of extracellular vesicles in cancer progression

The advent of cell phones, the internet, and various messaging platforms has allowed for faster and broader communication worldwide.

10 Nov 2022

Researchers discover residual tumor cells responsible for colon cancer relapse

Colon cancer is the third most common cancer in the world, with about 2 million new cases each year. Most patients are diagnosed when the tumor is still located in the colon or rectum.

9 Nov 2022

Protein complex may present strong therapeutic target for lethal breast cancer

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that a protein complex that governs gene expression (called CoREST) sometimes gets rewired during breast cancer to help estrogen receptor positive (ER+) tumors resist endocrine therapies and become more aggressive.

8 Nov 2022

Cell competition could be responsible for cancer relapses, study shows

A normal process called cell competition, in which healthy tissues eliminate unhealthy cells, could be responsible for cancer relapses in patients months or years after they were declared cancer-free, a new study by UT Southwestern Simmons Cancer Center researchers suggests.

8 Nov 2022

Combining chemotherapy with an inflammation inhibitor can prevent breast cancer metastasis

A new treatment developed at Tel Aviv University may significantly enhance the efficacy of chemotherapy in breast cancer patients, reducing the risk for lung metastasis following chemo from 52% to only 6%.

7 Nov 2022

Higher viscosity of extracellular fluid enhances cancer dissemination

New research findings show how higher viscosity, or resistance to flow, of the extracellular fluid that surrounds cells enables cancer cells to migrate more rapidly from a primary tumor to other sites in the body.

2 Nov 2022

UT Southwestern study uncovers a causative signaling pathway in breast cancer

UT Southwestern researchers have identified a causative signaling pathway in breast cancer, providing potential new targets for treatment of the most common type of cancer in women.

1 Nov 2022

First preclinical model to study the pathobiology of appendiceal cancer

Appendiceal cancer (malignancies of the appendix, a small tissue pouch that is part of the gastrointestinal tract) is very rare, occurring in perhaps one or two people per 1 million per year.

1 Nov 2022

Pitt researchers receive $792,000 to understand the biology behind ovarian cancer metastasis

Most women diagnosed with metastatic ovarian cancer have a less than five year survival rate. Researchers at the University of Pittsburgh Swanson School of Engineering are working to change that.

1 Nov 2022

BCRF renews funding to support the development of novel therapeutics for triple-negative breast cancer

The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna Irie, MD, PhD, to study new therapeutic approaches that target aggressive triple-negative breast cancer.

31 Oct 2022

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.

28 Oct 2022

Advanced type of nanoparticle could help fight hard-to-treat cancers

Nanoparticles, or tiny molecules that can deliver a payload of drug treatments and other agents, show great promise for treating cancers.

27 Oct 2022

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

In this interview, Dr. Shebna Massey discusses neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and more. She also discusses and explores new therapeutic targets and biomarkers for these diseases.

From Sino Biological Inc. 26 Oct 2022

UArizona researchers working on a less toxic treatment for deadly breast cancer

After decades of research and two previous drug development attempts, things are looking promising for a team of University of Arizona researchers working on a less toxic treatment for a specific type of breast cancer.

25 Oct 2022

Combination treatment improves progression-free survival in patients with oligometastatic prostate cancer

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer.

25 Oct 2022